Sugi Predict

Sugi Predict / Compounds / SCHEMBL195451

SCHEMBL195451

SCHEMBL195451

Cc1ccc(NC(=O)Nc2sc(C(C)(C)C)nc2C(=O)N2CCN(C)C(=O)C2(C)C)cc1-c1ccc(CN2CCOCC2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 3/20 0.39
▸ RAF1 P04049 5/20 0.39
▸ ABL1 P00519 4/20 0.39
▸ LYN P07948 3/20 0.39
▸ MAPK9 P45984 3/20 0.39
▸ SRC P12931 1/20 0.39
▸ BRAF P15056 3/20 0.38
▸ EPHA3 P29320 2/20 0.38
▸ EGFR P00533 1/20 0.38
▸ EPHA2 P29317 1/20 0.38
▸ AKT1 P31749 1/20 0.38
▸ FLT3 P36888 10/20 0.36
▸ PDE7A Q13946 1/20 0.35
▸ RET P07949 2/20 0.35
▸ KDR P35968 2/20 0.34
▸ BMPR1B O00238 1/20 0.34
▸ MUSK O15146 1/20 0.34
▸ EPHB6 O15197 1/20 0.34
▸ MAP3K7 O43318 1/20 0.34
▸ RIPK2 O43353 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13487855 0.94 HIF1A (0.38) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL3217181 0.88 FLT3 (0.36) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL196602 0.88 MAPK14 (0.40) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL195725 0.85 MAPK14 (0.42) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL3218816 0.85 MAPK14 (0.37) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL13487806 0.85 RAF1 (0.37) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL13487805 0.84 RAF1 (0.40) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL3197206 0.84 RAF1 (0.42) MAPK14RAF1ABL1LYNMAPK9
SCHEMBL3212515 0.84 RAF1 (0.36) MAPK14RAF1ABL1BRAFEGFR
SCHEMBL3209128 0.83 CNR2 (0.38) MAPK14RAF1ABL1LYNMAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2012500223-A — — 2012-01-05 — — JP claimed
WO-2010019930-A1 UREA DERIVATIVES AS INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — WO claimed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — US claimed
WO-2010019930-A1 UREA DERIVATIVES AS INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — WO disclosed
WO-2010019930-A1 UREA DERIVATIVES AS INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — WO disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — US disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — US disclosed
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2010-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041642-A1 UREA INHIBITORS OF MAP KINASES MAP4K2, MAP3K1, MAP3K20 MAPK14 33/4885RAF1 74/4885ABL1 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.